By Bhanvi Satija and Marleen Kaesebier
LONDON, Nov 19 (Reuters) – Swiss drugmaker Novartis set a target of annual sales growth of 5% through 2031 on Thursday, relying on a handful of drugs already on the market to offset looming patent expiries and recover from a string of late-stage trial setbacks.
The new target, at constant currencies, is lower than a 5% to 6% annual sales growth range it set last year for 2025-2030.
Shares in the company fell 2% in early trading.
Novartis is seeking to boost investor confidence in its growth plans beyond 2030 after several late-stage clinical study setbacks this year led to a $2.2 billion writedown in the third quarter.
By 2031, breast cancer drug Kisqali and Cosentyx for autoimmune diseases, two of Novartis’ best-selling medicines, will face competition from cheaper rivals. Its heart drug Entresto is already seeing tough generic competition and is set to lose $4 billion in sales this year.
The setbacks included the failure of del-desiran, a muscle weakness therapy that Novartis acquired as part of its $12 billion Avidity deal. That has drawn close investor scrutiny to CEO Vas Narasimhan’s dealmaking strategy.
Narasimhan said that the company’s mid-term targets do not assume any large acquisitions.
“We would expect the contribution of M&A and BD (business development) to be consistent with what we’ve done in the past,” he said.
Narasimhan said he expected most of the company’s growth beyond 2031 to come from medicines developed internally.
In the last decade, Novartis has spent over $100 billion on developing medicines internally and $63 billion on business development activities including acquisitions.
Cosentyx and Kisqali are expected to bring in combined sales of $14 billion in 2031, down from $16.6 billion in 2030, according to Visible Alpha estimates.
The company expects sales from its anti-inflammatory drug Rhapsido and multiple sclerosis drug Kesimpta, among others, to offset some of that drop in sales.
It forecast peak sales of Kisqali at $10 billion, and lifted its peak sales forecast for Kesimpta to $8 billion from $6 billion, and for leukemia drug Scemblix and cholesterol-lowering treatment Leqvio to $5 billion each from $4 billion.
(Reporting by Bhanvi Satija and Marleen Kaesebier;Editing by Dave Graham and Emelia Sithole-Matarise)

